[{"id":"87def125-04a6-4b33-bb5e-5e9e6e36a732","acronym":"Endouble","url":"https://clinicaltrials.gov/study/NCT05203276","created_at":"2022-01-24T17:01:44.348Z","updated_at":"2024-07-02T16:35:45.136Z","phase":"Phase 2","brief_title":"Envafolimab Combined With Endostar in the First-line Treatment of Advanced NSCLC","source_id_and_acronym":"NCT05203276 - Endouble","lead_sponsor":"The First People's Hospital of Lianyungang","biomarkers":" EGFR • PD-L1 • ALK • ROS1","pipe":"","alterations":" ","tags":["EGFR • PD-L1 • ALK • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Enweida (envafolimab) • Endostar (recombinant human endostatin)"],"overall_status":"Recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 03/01/2022","start_date":" 03/01/2022","primary_txt":" Primary completion: 05/30/2024","primary_completion_date":" 05/30/2024","study_txt":" Completion: 06/30/2024","study_completion_date":" 06/30/2024","last_update_posted":"2023-06-22"},{"id":"4eff10cc-05a2-4b86-ace5-1d1c8d8e33cc","acronym":"FTANLCNDG","url":"https://clinicaltrials.gov/study/NCT05574998","created_at":"2022-10-12T13:56:31.219Z","updated_at":"2024-07-02T16:36:02.720Z","phase":"Phase 2","brief_title":"First-Line Treatment of Advanced Non-Small-Cell Lung Cancer With Negative Driver Gene: a Multicenter, Single-Arm Trial","source_id_and_acronym":"NCT05574998 - FTANLCNDG","lead_sponsor":"Qianfoshan Hospital","biomarkers":" EGFR • ALK • ROS1","pipe":" | ","alterations":" EGFR mutation","tags":["EGFR • ALK • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • carboplatin • paclitaxel • pemetrexed • Endostar (recombinant human endostatin)"],"overall_status":"Recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 02/01/2021","start_date":" 02/01/2021","primary_txt":" Primary completion: 02/01/2024","primary_completion_date":" 02/01/2024","study_txt":" Completion: 04/01/2024","study_completion_date":" 04/01/2024","last_update_posted":"2022-10-11"},{"id":"3bf89e88-6b33-4e55-947a-8b03ad1b7034","acronym":"","url":"https://clinicaltrials.gov/study/NCT04942301","created_at":"2021-06-28T17:52:43.420Z","updated_at":"2024-07-02T16:36:28.490Z","phase":"Phase 1","brief_title":"PK Study for Endostar Continuous Intravenous Infusion in NSCLC Patients With 1st-line Platinum Based Chemotherapy","source_id_and_acronym":"NCT04942301","lead_sponsor":"Jiangsu Simcere Pharmaceutical Co., Ltd.","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Endostar (recombinant human endostatin)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 24","initiation":"Initiation: 07/30/2021","start_date":" 07/30/2021","primary_txt":" Primary completion: 12/25/2021","primary_completion_date":" 12/25/2021","study_txt":" Completion: 10/15/2022","study_completion_date":" 10/15/2022","last_update_posted":"2021-06-30"},{"id":"b1d41407-6184-43a2-a661-394aa0614168","acronym":"","url":"https://clinicaltrials.gov/study/NCT04447326","created_at":"2021-01-18T21:24:01.643Z","updated_at":"2024-07-02T16:36:43.816Z","phase":"Phase 2","brief_title":"Toripalimab, Endostar Combined With Radiotherapy and Chemotherapy for Nasopharyngeal Carcinoma","source_id_and_acronym":"NCT04447326","lead_sponsor":"First Affiliated Hospital of Guangxi Medical University","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Loqtorzi (toripalimab-tpzi) • Endostar (recombinant human endostatin)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 106","initiation":"Initiation: 06/01/2020","start_date":" 06/01/2020","primary_txt":" Primary completion: 06/01/2024","primary_completion_date":" 06/01/2024","study_txt":" Completion: 06/01/2026","study_completion_date":" 06/01/2026","last_update_posted":"2020-06-25"},{"id":"f34581ca-500e-4f8e-9aec-461e0ce61350","acronym":"ENPOWER","url":"https://clinicaltrials.gov/study/NCT04063449","created_at":"2021-01-18T19:54:42.929Z","updated_at":"2024-07-02T16:36:56.715Z","phase":"","brief_title":"Endostar/PD-1 Inhibitors Combined With PP for Advanced NSCLC","source_id_and_acronym":"NCT04063449 - ENPOWER","lead_sponsor":"Dong Wang","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • Tyvyt (sintilimab) • Endostar (recombinant human endostatin)"],"overall_status":"Unknown status","enrollment":" Enrollment 170","initiation":"Initiation: 08/20/2019","start_date":" 08/20/2019","primary_txt":" Primary completion: 06/30/2020","primary_completion_date":" 06/30/2020","study_txt":" Completion: 06/30/2021","study_completion_date":" 06/30/2021","last_update_posted":"2019-08-21"},{"id":"aca2f396-9153-412a-a548-4b2570f47f76","acronym":"","url":"https://clinicaltrials.gov/study/NCT03907098","created_at":"2021-01-18T19:13:59.555Z","updated_at":"2024-07-02T16:37:00.805Z","phase":"Phase 2","brief_title":"Endostar in Combination With Chemotherapy in HER-2 Negative Advanced Breast Cancer","source_id_and_acronym":"NCT03907098","lead_sponsor":"Zhejiang Cancer Hospital","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Endostar (recombinant human endostatin)"],"overall_status":"Unknown status","enrollment":" Enrollment 50","initiation":"Initiation: 06/30/2016","start_date":" 06/30/2016","primary_txt":" Primary completion: 12/30/2019","primary_completion_date":" 12/30/2019","study_txt":" Completion: 06/30/2020","study_completion_date":" 06/30/2020","last_update_posted":"2019-04-08"},{"id":"a8cff956-2a76-410b-8df6-b92309b9359d","acronym":"","url":"https://clinicaltrials.gov/study/NCT03706703","created_at":"2021-01-18T18:09:45.395Z","updated_at":"2024-07-02T16:37:05.997Z","phase":"Phase 2","brief_title":"Rh-Endostatin (Endostar®) Continuous Intravenous Infusion","source_id_and_acronym":"NCT03706703","lead_sponsor":"Affiliated Cancer Hospital \u0026 Institute of Guangzhou Medical University","biomarkers":" EGFR • ALK • ROS1","pipe":" | ","alterations":" EGFR mutation • RET mutation","tags":["EGFR • ALK • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • RET mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • docetaxel • pemetrexed • Endostar (recombinant human endostatin)"],"overall_status":"Unknown status","enrollment":" Enrollment 50","initiation":"Initiation: 10/01/2018","start_date":" 10/01/2018","primary_txt":" Primary completion: 04/01/2020","primary_completion_date":" 04/01/2020","study_txt":" Completion: 09/01/2020","study_completion_date":" 09/01/2020","last_update_posted":"2018-10-17"},{"id":"f34e556e-827e-43c1-91d0-67f812ccd954","acronym":"","url":"https://clinicaltrials.gov/study/NCT03008109","created_at":"2021-01-18T14:47:58.365Z","updated_at":"2024-07-02T16:37:26.743Z","phase":"Phase 3","brief_title":"Endostar Plus EGFR-TKI（Epidermal Growth Factor Receptor-Tyrosine-Kinase Inhibitor） as a Treatment of EGFR Mutation-positive NSCLC","source_id_and_acronym":"NCT03008109","lead_sponsor":"Zaiwen Fan","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Endostar (recombinant human endostatin)"],"overall_status":"Unknown status","enrollment":" Enrollment 80","initiation":"Initiation: 02/01/2017","start_date":" 02/01/2017","primary_txt":" Primary completion: 11/01/2017","primary_completion_date":" 11/01/2017","study_txt":" Completion: 11/01/2018","study_completion_date":" 11/01/2018","last_update_posted":"2017-01-04"},{"id":"6dd650b0-d07e-40b8-81a5-bed6597d302d","acronym":"","url":"https://clinicaltrials.gov/study/NCT02579564","created_at":"2021-01-18T12:30:32.393Z","updated_at":"2024-07-02T16:37:28.336Z","phase":"Phase 3","brief_title":"Systemic Chemotherapy Combined With Recombinant Human Adenovirus Type 5 and Endostatin Injections for Treatment Malignant Hydrothorax in NSCLC Patients","source_id_and_acronym":"NCT02579564","lead_sponsor":"Xinqiao Hospital of Chongqing","biomarkers":" EGFR • MUC16","pipe":"","alterations":" ","tags":["EGFR • MUC16"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • gemcitabine • paclitaxel • pemetrexed • vinorelbine tartrate • Endostar (recombinant human endostatin) • Oncorine (recombinant human adenovirus type 5)"],"overall_status":"Unknown status","enrollment":" Enrollment 134","initiation":"Initiation: 10/01/2016","start_date":" 10/01/2016","primary_txt":" Primary completion: 06/01/2018","primary_completion_date":" 06/01/2018","study_txt":" Completion: 12/01/2018","study_completion_date":" 12/01/2018","last_update_posted":"2016-10-21"},{"id":"a4c3a7fc-2c8f-4d4c-b46c-1b5489b00056","acronym":"","url":"https://clinicaltrials.gov/study/NCT02865304","created_at":"2021-01-18T14:03:58.703Z","updated_at":"2024-07-02T16:37:29.808Z","phase":"Phase 3","brief_title":"The Efficacy and Safety of Endostar Combined With Taxane-based Regimens for HER-2-negative MBC Patients","source_id_and_acronym":"NCT02865304","lead_sponsor":"Fujian Cancer Hospital","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Endostar (recombinant human endostatin)"],"overall_status":"Unknown status","enrollment":" Enrollment 80","initiation":"Initiation: 12/01/2016","start_date":" 12/01/2016","primary_txt":" Primary completion: 12/01/2017","primary_completion_date":" 12/01/2017","study_txt":" Completion: 12/01/2018","study_completion_date":" 12/01/2018","last_update_posted":"2016-08-12"},{"id":"f4488597-414b-4206-9df3-12afd90921ad","acronym":"","url":"https://clinicaltrials.gov/study/NCT02804646","created_at":"2021-01-18T13:45:10.328Z","updated_at":"2024-07-02T16:37:31.130Z","phase":"Phase 4","brief_title":"Endostar Durative Transfusion Combined With Chemotherapy in the Treatment of Advanced Lung Adenocarcinoma","source_id_and_acronym":"NCT02804646","lead_sponsor":"Anhui Provincial Hospital","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR wild-type • ALK wild-type • EGFR wild-type + ALK wild-type • ALK negative","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR wild-type • ALK wild-type • EGFR wild-type + ALK wild-type • ALK negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • carboplatin • pemetrexed • Endostar (recombinant human endostatin)"],"overall_status":"Unknown status","enrollment":" Enrollment 100","initiation":"Initiation: 06/01/2016","start_date":" 06/01/2016","primary_txt":" Primary completion: 12/01/2017","primary_completion_date":" 12/01/2017","study_txt":" Completion: 12/01/2018","study_completion_date":" 12/01/2018","last_update_posted":"2016-06-21"}]